UBV
VTGN icon

United Bank (Virginia)’s VistaGen Therapeutics VTGN Stock Holding History

United Bank (Virginia)’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-667
Closed -$2.5K – 165
2023
Q1 		$2.5K Hold
667
– – ﹤0.01% 160
2022
Q4 		$2.06K Hold
667
– – ﹤0.01% 158
2022
Q3 		$3K Sell
667
-598
-47% -$5.93K ﹤0.01% 158
2022
Q2 		$33K Buy
+1,265
New +$44.7K ﹤0.01% 145

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

United Bank (Virginia)'s VTGN Position: Q2 2023 in Review

United Bank (Virginia) sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 667 shares — an estimated $2.5K sold.

United Bank (Virginia) first reported a position in VTGN in Q2 2022 and held it in 4 quarters. The position peaked at $33K in Q2 2022. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • United Bank (Virginia) reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • United Bank (Virginia) sold 667 VistaGen Therapeutics shares in Q2 2023, an estimated $2.5K.
  • United Bank (Virginia) first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 4 quarters.
  • United Bank (Virginia)'s VistaGen Therapeutics position peaked at $33K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on United Bank (Virginia)'s 13F filing for Q2 2023, filed 3 Aug 2023.